Millennium Pharmaceuticals Inc.

Chief Responsibility: Strategic planning and oversight of research and drug discovery programs that deliver novel therapeutics for the treatment of cancer. Experience: Dr. Bolen has extensive research and management experience. Prior to joining Millennium, he was Vice President and Global Head of Oncologic Diseases at Hoechst Marion Roussel, Director of the Cellular Signaling Department at the DNAX Research Institute of Molecular and Cellular Biology, Executive Director of Oncology Drug Discovery at the Bristol-Myers Squibb Pharmaceutical Research Institute, Professor and Member of the Graduate Faculty at Princeton University, a graduate advisor at the Robert Wood Johnson Medical School, Section Chief of the Biochemical Oncology Department and founding member of the Laboratory of Tumor Virus Biology at the National Cancer Institute. Dr. Bolen has published more than 200 peer-reviewed scientific articles, reviews and book chapters and has served on numerous international journal editorial boards. He has served on study sections, panels and committees for the National Institutes of Health, the American Association for Cancer Research, the National Science Foundation, the National Aeronautics and Space Administration, and the Howard Hughes Medical Institute. Awards: National Institutes of Health Award for Meritorious Research in 1990 Boards: Scientific Advisory Board, Hollings Cancer Center, and previously, Scientific Advisory Board, Center for Advanced Biotechnology & Medicine, Rutgers University Education: Post-doctoral training in Molecular Virology, Kansas State University Cancer Center Doctor of Philosophy in Immunology and Bachelor of Science in Microbiology and Chemistry from the University of Nebraska One of my favorite quotes: "The mark of an educated individual is to demand no more precision from a subject than the subject itself allows." Aristotle In my own words: At Millennium: I direct all of the Research and Drug Discovery functions. I joined the company in 1999 as Vice President of Oncology. Our research teams are driving breakthrough science by capturing their human and scientific passion for developing new medicines for people with life threatening and debilitating diseases. Millennium research and drug discovery scientists – like thousands of other oncology pharmaceutical researchers around the globe, do what we do for reasons far more noble than the generation of corporate profit. We are collectively the innovative and creative 'drug hunters and craftsmen' of the industry and – fully understanding the enormous challenge of our mission – represent perhaps the largest congregation of optimists in the galaxy. The main reason I chose my field: I did not choose cancer research as my life's work, it chose me. While my Ph.D. work was in the field of Cellular Immunology, I chose Animal Virology as a field for post-doctoral training. My intent was simply to understand more about how animal viruses could be used to gain knowledge about more complex biological systems much in the way bacterial viruses were used to gain insight into the biology of bacteria. This happened during the mid 1970's when animal tumor virus research was beginning shed some light on the genetic basis of cancer. The virus that I worked on as a post doctoral fellow turned out to be one of those viruses that could cause cancer in rodents although how this occurred was unknown. Following my post-doctoral training I joined the National Institutes of Health where I focused on trying to understand the molecular mechanism through which this virus caused cancer in animals. I was fortunate to be one of the scientists who helped solve this mystery in the mid 1980's by demonstrating that a single virus encoded protein bound to and activated host cell signal transduction enzymes leading to cancer. As it turned out, many of these same enzymes are now known to play similar roles in the genesis of human cancer. Thus, my fascination and simple curiosity about how viruses could induce cancer in animals set the path that I have followed for almost 30 years. The other side of me: Outside of work, a personal passion of mine is music. I made a living during the late 1960's and early 1970's as a musician (drums & guitar) in a band (mostly Rock & Roll and Blues) touring throughout the Midwest. I still play my guitar on occasion.

Chief Responsibility: Dr. Bianchi's organization (marketing, sales, medical affairs, new products, government affairs, pharmaceutical and commercial operations) is responsible for advancing the global competitive standing of all Millennium brands. The objective is to maximize the impact of our marketed brands in delivering benefits for the patients, healthcare providers, payers and shareholders. Experience: Dr. Bianchi joined Millennium in February 2006 with 17 years of experience in the U.S. pharmaceutical industry. He has built commercial and sales organizations, launched major brands, delivered sustained growth, and managed collaboration with partner companies. Dr. Bianchi came from sanofi-aventis where he led the $2 billion U.S. oncology business unit with the well-known brands Eloxatin® and Taxotere. Previously at sanofi-synthelabo, Dr. Bianchi headed the internal medicine and central nervous system business unit with sales of $1.2 billion. Dr. Bianchi also had a very successful 10-year career at Rhone-Poulenc Rorer, where he last served as vice president - head of global marketing and led many of the commercial efforts for the market-leading antithrombotic, Lovenox®. Board: Penwest Pharmaceuticals Education: Doctor of Medicine from the University of Reims-Champagne in France MBA from the Wharton School at the University of Pennsylvania One of my favorite quotes: "Imagination is more important than knowledge" Albert Einstein In my own words: At Millennium: People, people, people: they make things happen and make the difference. Plus there is VELCADE: it makes the difference for the patients and their families. The main reason I chose my field: First, I could not join the US PGA tour. Second, pharmaceuticals have always been fascinating to me. They cost more than several jumbo jets to develop; yet they ultimately are consumer goods. The development of pharmaceuticals is the single most important contributor to the improvement of human health that we have seen in the past century and I am proud to be a very small part of it. The other side of me: Outside of work what am I passionate about? In no particular order: Coltrane, Miles, modern architecture, Sunday morning on Park Avenue, cold Champagne...and I keep working on my golf game hoping that, some day, I might finally qualify, if not for the PGA tour, at least for my club's championship. divider

Chief Responsibility: Providing strategic leadership and driving strategic transactions that accelerate Millennium's path to leadership in oncology. Experience: Ms. Protopapas came to Millennium with a diverse set of experiences including process engineering for a pharmaceutical company, US and international (Europe and Japan) marketing for the health care division of a consumer products company and business development for a technology start-up. Boards: Ensemble Discovery, Kingsley School Board of Trustees Education and Awards: Masters in Business Administration from Stanford Business School Masters in Engineering (Chemical Engineering: Summa Cum Laude) from Massachusetts Institute of Technology Bachelor of Science in Engineering (Chemical Engineering: Magna Cum Laude, Sigma Xi, Tau Beta Phi) from Princeton University One of my favorite quotes: "The energy of the mind is the essence of life." Aristotle. In my own words: At Millennium: During more than a decade at Millennium, I've led the planning and execution of over twenty strategic alliances that have brought two billion dollars in funding, downstream capabilities and assets. I have also helped transform the company twice during this time: first from an early stage genomics company to a fully integrated biotechnology company and subsequently into a biotechnology company focused on profitability and growth. While all this has been exciting, my work helping organize and consummate our acquisition by Takeda Pharmaceuticals has been the most gratifying. Additionally, my work leading the integration efforts to transition Millennium into the independent oncology subsidiary of Takeda has been fascinating and rewarding. With all these changes at Millennium in the past decade, our core attributes of vibrancy of intellect and passion for innovation have remained the same. The main reason I chose my field: Excitement for scientific innovation and the difference it can make in our day-to-day lives combined with an early realization that Wimbledon was not a future option. The other side of me: Hanging out with my husband Tom; parenting (with occasional success) Nikolas, Sofia and Eleni; perfecting my chocolate mousse and a deep yearning for the Mediterranean sun.

Chief Responsibility: Ms. Keating is responsible for setting the Company's legal, intellectual property and corporate quality strategies and priorities. She has the privilege of leading the very talented professionals in those organizations who tirelessly and proactively support the Company's global leadership goals, its commercial initiatives and its endeavors to bring important new medicines to patients. Experience: Co-founder and first CEO of Hydra Biosciences, Inc., a venture backed biotech company focused on developing drugs targeting novel ion channels. After joining Millennium in 2004, Ms. Keating remained a member of the Board of Directors of Hydra through 2007. Prior to Hydra, Ms. Keating served as an executive at high growth technology companies, including serving as Senior Vice President, General Counsel and Secretary of Iomega Corporation, a data storage company, and Sybase, Inc., a software company that grew from a few hundred to 6,000 employees during Ms. Keating's tenure on the management team. Based on her leadership at Sybase, Ms. Keating was named as one of the 45 most influential in-house lawyers in the United States under the age of 45. Upon graduating from law school, Ms. Keating practiced law at McCutchen, Doyle, Brown and Enersen (now Bigham McCutchen) in San Francisco. Education: Doctor of Jurisprudence from the University of California, Hastings College of the Law, graduating Order of the Coif and winning election to the Thurston Honor Society Bachelor of Science in Economics from the University of California at Berkeley Boards/Committees: Massachusetts Biotechnology Council, the Boston Public Library Foundation, and the Executive Committee of BIO's General Counsel Committee One of my favorite quotes: "Whatever you can do or dream you can, do it. Boldness has genius, power and magic in it." Goethe In my own words: At Millennium: I work closely with my colleagues across the Company in executing ambitious, compliant plans that capture opportunities to bring the Company's medicines to patients more quickly and keep Millennium on track to become one of the top oncology companies in the world. Our Company has an exceptional patent estate protecting the inventions of our outstanding scientists; it also has a quality and compliance record all employees can be very proud of. I take particular interest in our Company's corporate and clinical development activities, doing all that we can to make our Company a partner and sponsor of choice. People see me and I see myself as a problem solver determined to get things done. The main reason I chose my field: I decided to become a lawyer after reading Gideon's Trumpet and John Hersey's The Algiers Motel Incident. My entrepreneurial drive and love of building businesses took me from the law firm setting into growth companies. After co-founding Hydra Biosciences, I knew that for me the challenge and excitement of science-based companies developing new medicines for patients in dire need of new therapies were compelling. Building Millennium into a leading oncology company fires me up. The other side of me: When not working, what floats my boat is the time my husband and I have with our two teenage sons, whether we're hiking, skiing, sailing, playing tennis, exploring new places and cultures, or just taking in a movie, walking on a beach or cheering at soccer and basketball games! For more than thirty years I've collected children's literature and I'm constantly searching for exciting new authors...and more bookshelf space.

Paul Hamelin was appointed President in November 2008 after joining us in May 2006 as Senior Vice President, Commercial Operations. From March 2006 until May 2006, Mr. Hamelin was Managing Director of Rosemont. From 2004 to 2005 Mr. Hamelin served as President and Chief Operating Officer at Algorx Pharmaceuticals. Prior to joining Algorx he held the positions of President and Chief Executive Officer of Elitra Pharmaceuticals, Inc. from 2002 to 2004 and Senior Vice President, Global Commercial Operations at Millennium Pharmaceuticals, Inc. from 2000 to 2002. Prior to Mr. Hamelin’s experience at specialty and biotech companies, for over 20 years he held senior management marketing, sales and commercial operations positions at several large pharmaceutical companies including Pharmacia/Searle, Abbott Labs and Eli Lilly. He is also a Registered Pharmacist.

Dr. Smith joined Millennium in 2001 as Senior Vice President, Drug Safety & Disposition and Comparative Medicine with more than 20 years of experience in the U.S. pharmaceutical industry. Today, he is responsible for the preclinical development, comparative medicine and pharmaceutical sciences areas for all discovery and development programs. Prior to joining Millennium, Dr. Smith was a Vice President at Pharmacia, where he led a global metabolism and investigative sciences department of more than 300 scientists. Previously at Searle/Monsanto, Dr. Smith led the Metabolism and Safety Evaluation department. In this role he was responsible for the preclinical development of the Cox-2 inhibitors Celebrex and Bextra ; the antimineralocorticoid Inspra and the glycoprotein IIb/IIIa antagonists, xemilofiban and orbofiban. Earlier in his career, Dr. Smith served as a Senior Research Toxicologist and Research Fellow in the Safety Assessment Department at Merck Research Laboratories, where he developed extensive project team experience working with leading pharmaceutical agents, including Mevacor , Zocor , Hyzaar , Fosamax and Proscar . Dr. Smith earned a bachelor's degree in Biology from Fairfield University, received a Ph.D. in Pharmacology and Toxicology from the University of Arizona, and completed a post-doctoral fellowship in Biochemical Toxicology at Smith Kline and French Laboratories.

Chief Responsibility: Providing human resources, information technology facilities and safety services to the employees of Millennium Experience: Mr. Gansler has more than 25 years of experience in senior Human Resources leadership roles. He joined Millennium from Synta Pharmaceuticals where he was Senior Vice President of Human Resources for this privately held biopharmaceutical start-up. Previously, he headed Human Resources for Covanta Energy Corp and four business units within the Johnson & Johnson Family of Companies. He began his career at General Motors Corp. Education: Doctor of Jurisprudence degree and Masters in Business Administration from Seton Hall University in South Orange, NJ Bachelor of Industrial Administration from Kettering University in Flint, Mich. One of my favorite quotes: "Courage is what it takes to stand up and speak, Courage is also what it takes to sit down and listen." Sir Winston Churchill In my own words: At Millennium: I oversee all human resource functions and help assure that employees have a voice and are supported in their efforts to make a visible contribution to the success of our company. This requires an environment that affords employees career development and growth. We celebrate individual and team success through recognition and rewards. Our culture is supportive and caring, yet demands excellence, innovation, and integrity. We enjoy an entrepreneurial spirit and lack of bureaucracy. Quite simply, it's our people and our culture that make all the difference, and it's my job to make sure these critical assets are properly developed and that we continue to attract and retain people who are capable of sustainably growing our success. The main reason I chose my field: The chance to drive business results through an understanding of forces that engage employees in the business and encourages achievement. The other side of me: Outside of work, a personal passion of mine is time with my family, and in particular having fun scuba diving, snorkeling and boating.

David Schenkein, Board Member: David is the VP of Oncology Development at Millennium Pharmaceuticals and is the co-founder of the Neely Foundation where he currently sits on the Board of Directors. Prior to Millennium, David was the director the Tufts New England Medical Center (NEMC) cancer center. Through the Neely Foundation and other charitable groups, David is extremely active in the healthcare philanthropic community and as a BOD member of CAVU brings a wealth of knowledge and experience.

Chief Responsibility: Oversee internal and external communications to achieve and maintain best-in-class performance that is a competitive advantage for Millennium. Areas of responsibility include media relations, employee communications, branding & reputation management, visual arts, issue & crisis management, patient advocacy, corporate philanthropy & social responsibility, and community relations. Experience: Ms. Adler joined Millennium in 2004 with more than 20 years experience in healthcare communications. Prior to joining Millennium, she was an executive vice president and managing director at Feinstein Kean Healthcare (Ogilvy Public Relations subsidiary), where she was charged with building, expanding and overseeing the pharmaceutical communications practice. Her clients included Novartis Pharmaceuticals, Johnson & Johnson, Pfizer and Merck Vaccines. Much of Ms. Adler's experience has been in the areas of new product launches, national, multi-year direct-to-patient initiatives, third-party coalition building and managing corporate/product crisis and issues. Previously, she was associate director for the Johnson & Johnson U.S. Pharmaceuticals Group. Earlier in her career, Ms. Adler worked for Porter/Novelli Public Relations and Manning, Selvage & Lee. Education: Bachelor of Science from the University of Massachusetts at Amherst One of my favorite quotes: "To be persuasive, we must be believable To be believable, we must be credible To be credible, we must be truthful." Edward R. Murrow In my own words: At Millennium: I lead a team of highly talented communications professionals who work hard to develop and deliver innovative, exciting communications inside and outside our company. We strive to provide every employee a 360-degree line of sight around our company so they can share in all our successes and better relate with our overall business plan and operations. Outside of the company, as part of the Takeda acquisition, we oversee corporate repositioning, branding and corporate advertising. Working at Millennium is an incredible opportunity to be a part of a very entrepreneurial Management Team in a fast-paced environment that demands quick, strategic thinking. It is invigorating and demands my best. I admire the competence and skill of my peers and the extraordinary depth of talent within our company. The supportive team spirit thrives on over-achieving and brings out the best in people. Plus, there's never a dull moment! The main reason I chose my field: The fast-paced nature of communications coupled with my desire to continuously learn more about medical science made this an ideal career for me. The other side of me: Outside of work, the most important thing to me is spending time with my husband and three teenage children. We love to travel and experience different cultures. But life at home is what I like best nothing makes me happier than having a home filled with family and friends (although it can get exhausting). And I'm passionate about staying active and fit.

Ms. Memon, who is based in Cambridge, Massachusetts, has extensive experience as a fundraiser and community leader in the Indian American, South Asian, and APA communities. She also has been very active with the Women's Leadership Forum of the Democratic National Committee and a Steering Committee Member for major Democratic Party events. Ms. Memon currently serves as a National Executive Board member for the Indian American Forum for Political Education (IAFPE). During her years in Washington, she was an active member of the Virginia Democratic Committee, a Board Member of VANARAL, and an Advisory Board Member for the Center for Multicultural Human Services (CMHS), a group dedicated to serving the mental health, social, and educational needs of new Americans and the international community in Metro D.C. Ms. Memon has an M.S. in Biotechnology from Johns Hopkins University and a B.S. from Northeastern University. She was included in "Who's Who Among Students in American Colleges and Universities" when she was President of Northeastern's International Student Forum. She currently serves as a Senior IP Specialist in the Biotechnical Patent Prosecution Team at Millennium Pharmaceuticals, Inc., located in Cambridge, MA.

Dr. Bensinger has disclosed that he serves as a consultant for Millennium Pharmaceuticals. He has received grant/research support from Celgene, Novartis, Biopharma, Amgen, MedImmune, and PDL. He also serves on speakers' bureaus for Celgene and Millennium.

Raju Kucherlapati is a Professor of Medicine and the Paul C. Cabot Professor of Genetics at Harvard Medical School and the first Scientific Director of the Harvard-Partners Center for Genetics and Genomics. Dr. Kucherlapati came to the United States in 1967 after completing undergraduate and graduate degrees in India. He received his Ph.D. from the University of Illinois at Urbana and did his post-doctoral work in the lab of Frank Ruddle at Yale University. He was assistant professor in the Department of Biochemical Sciences at Princeton University, and then became professor in the Department of Genetics at the University of Illinois College of Medicine. In 1989 Dr. Kucherlapati went to the Albert Einstein College of Medicine where he was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department of Molecular Genetics, a position he held for eleven years.

Eric S. Lander, Ph.D., is a co-founder of Infinity. Dr. Lander has been a Professor and Associate Professor of Biology at the Massachusetts Institute of Technology since 1990 and a Professor of Systems Biology at Harvard Medical School since 2004. Dr. Lander has served as the founding Director of The Eli and Edythe L. Broad Institute, a biomedical research institute formed by MIT and Harvard University, since 2003 and as a member of the Whitehead Institute for Biomedical Research since 1989. From 1993 - 2003, Dr. Lander was the Director of the Whitehead/MIT Center for Genome Research. Dr. Lander received an A.B. in Mathematics from Princeton University and a D.Phil. in Mathematics from Oxford University, which he attended as a Rhodes Scholar.

Jeffrey Leiden, MD, PhD has more than 20 years of experience in the biomedical and pharmaceutical sectors. Dr. Leiden was President and COO of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Abbott Board of Directors and the TAP Board of Directors from 2000-2006. From 1987-2000 Dr. Leiden held several academic appointments including Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. During his academic career, Dr. Leiden was involved in starting several biotechnology companies including Vical and Cardiogene. He is an elected member of both the American Academy of Arts and Sciences, and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden represents Clarus on the Board of Directors of TyRx Pharma, Inc., Biolex Therapeutics, and is Chairman of the Board of Variation Biotechnologies, Inc. Dr. Leiden is also a member of the Board of Directors of Milennium Pharmaceuticals, Inc. (MLNM), a non-executive director of Shire plc and a member of the Board of Trustees of the Ravinia Festival and the University of Pennsylvania School of Medicine. Dr. Leiden received both his medical degree and PhD from the University of Chicago and an honorary MA from Harvard University.

Mr. Levin is a partner of Third Rock Ventures, LLC, a venture capital firm (since September 2007). Previously he was Chairperson of the Board of Directors (March 1996 to July 2005), President (1993 to July 2005) and Chief Executive Officer (November 1994 to July 2005) of Millennium. Prior to joining Millennium, Mr. Levin was a Partner at Mayfield, a venture capital firm (1987 to 1994), and held various positions with Genentech, Inc., Foxboro Company, Miller Brewing Company and Eli Lilly and Company (1974 to 1987) in biochemical and process engineering, marketing and project leadership.

Mr. Wheelwright recently retired from his position as the Edsel Bryant Ford Professor of Business Administration at Harvard Business School. Professor Wheelwright first taught at Harvard from 1971-79 and was the Thomas Henry Carroll-Ford Foundation Visiting Professor from 1985-86. He rejoined the Harvard faculty in 1988. In his years away from Harvard, he was the Kleiner, Perkins, Caufield and Byers Professor of Management at Stanford University Graduate School of Business. Professor Wheelwright has a B.S. degree in Mathematics from the University of Utah and an M.B.A. and Ph.D. from Stanford University's Graduate School of Business. In addition to his Harvard and Stanford positions, Professor Wheelwright served on the faculty of INSEAD (European Institute of Management) in Fontainebleau, France. He was Vice President of Sales in a family-owned printing company and has consulted in the areas of business/operations strategy and improving product development capabilities. Professor Wheelwright currently serves as Chairman of the Board of HBS Publishing, and as a Board member at O.C. Tanner Company (service awards) Quantum Corporation (data storage), at Zions Bank (banking), and at CheckSum (circuit board testing equipment).